CORE--OUTPATIENT FACILITY

核心——门诊设施

• 批准号: 5206716
• 负责人: DEBORAH C MARCELLUS
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5206716
• 关键词: biomedical facility; bone marrow transplantation; graft versus host disease; human subject; human therapy evaluation; outpatient care; patient /disease registry; postoperative complications

The objectives of the Outpatient Facility are: 1. To provide a common resource for Project 1-5 The facilities of the Outpatient Clinic (OPD) are essential for the acquisition of clinical data required to accomplish the aims of the various projects. It is in the OPD that assessments of sustained engraftment, tumors response, acute and chronic GVHD, manifestations of immunodeficiency, post-engraftment infections and other complications of bone marrow transplant are made. As well as clinical evaluations, the OPD provides a means for procuring blood and tissue specimens for multiple investigators. 2. To provide a systematic approach to the evaluation and management of late complications. The incidence and severity of multiple organ toxicities after BMT is under active investigation. A systematic approach to the follow-up of all patients will allow us to determine the contribution of multiple factors (such as age, preparative regimen, type of transplant, post-transplant immunosuppression) to the risk for the toxicities observed. In addition, it is anticipated that management approaches to the complications identified will be developed and investigated. 3. To prospectively evaluate chronic GVHD A systematic evaluation of patients with chronic GVHD will be carried out. A staging system for this condition will be developed as outlined in Project 2. Patients and clinical specimens for Phase II and Phase III therapeutic studies descried in Project 2 will be obtained in the OPD.

门诊设施的目标是： 1. 为项目1-5提供公共资源 门诊诊所的设施是必要的， 获取实现目标所需的临床数据 各种项目。 正是在OPD中， 移植，肿瘤反应，急性和慢性GVHD， 免疫缺陷，植入后感染和其他并发症 进行骨髓移植。 除了临床评价外， OPD提供了一种获取血液和组织样本的方法， 多名调查员 2. 提供一个系统的方法来评价和管理 晚期并发症 多器官损害的发生率和严重程度 BMT后的毒性正在积极研究中。 一个系统 对所有患者进行随访的方法将使我们能够确定 多种因素（如年龄、准备方案、类型）的贡献 移植，移植后免疫抑制）的风险 观察到的毒性。 此外，预计管理层 将制定解决已确定的并发症的方法， 研究了 3. 前瞻性评价慢性GVHD 对慢性GVHD患者进行系统评价 出去 一个分期系统为这种情况将制定概述 在项目2中。 II期和III期的患者和临床标本 项目2中描述的III类治疗研究将在 门诊部